How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/locally-advanced-or-metastatic-anaplastic-thyroid-cancer-atc-with-braf-v600e-mutation.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
Mekinist	trametinib	Novartis	Kinase Inhibitor	Dual specificity mitogen-activated protein kinase kinase 2		2013-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Novartis · 1 drug in Locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation:

Cite this brief

Drug Landscape (2026). Locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/locally-advanced-or-metastatic-anaplastic-thyroid-cancer-atc-with-braf-v600e-mutation. Accessed 2026-06-10.

Locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing